MAUDE Adverse Event Report: PULMONX CORPORATION ZEPHYR ENDOBRONCHIAL VALVE

Model Number	ZEPHYR 5.5 EBV
Medical Device Problem Code	Adverse Event Without Identified Device or Use Problem (2993)
Health Effect - Clinical Code	Pneumothorax (2012)
Date of Event	10/16/2023
Type of Reportable Event	Serious Injury
Event or Problem Description
The patient had a bronchoscopic lung volume reduction procedure with four zephyr valves (three 4.0 ebvs, one 5.5 ebv) placed in the left upper lobe (lul) on (b)(6), 2023.The physician did a bronchoscopy on (b)(6), 2023 (standard practice per the physician), and the valves looked good.The patient was discharged on (b)(6), 2023 and returned within 24 hours with a tension pneumothorax.A chest tube was inserted and the patient was intubated on (b)(6), 2023.Two valves were removed on (b)(6), 2023; (5.5 ebv from the lingula and 4.0 ebv from anterior).On (b)(6), 2023, the remaining two 4.0 ebv valves in the apical and posterior were removed.As of (b)(6), 2023, the patient was still in the hospital with the chest tube in place.
Additional Manufacturer Narrative
Pneumothorax is the most common side effect associated with the zephyr valve treatment (criner et al.A multicenter randomized controlled trial of zephyr endobronchial valve treatment in heterogeneous emphysema (liberate).Am j respir crit care med.2018; 198 (9): 1151-1164).Targeted lobar deflation likely causes inflation of the ipsilateral lobe, which can result in a tear of the already compromised parenchymal tissue of the emphysematous ipsilateral lobe, resulting in a pneumothorax (criner et al.A multicenter randomized controlled trial of zephyr endobronchial valve treatment in heterogeneous emphysema (liberate).Am j respir crit care med.2018; 198 (9): 1151-1164).In the liberate study (ide clinical study used to support pma p180002's approval), (b)(4) of the zephyr valve subjects experienced a pneumothorax in the treatment period ([less than or equal to 45 days).These were managed using standard of care procedures as per previously published guidelines (valipour, arschang, et al.Respiration 87.6 (2014): 513-521).In (b)(4) of the events, the pneumothorax resolved without any additional intervention with subjects under careful observation.In over half the events ((b)(4)), the pneumothorax was managed with a chest-tube only.An additional (b)(4) of the events were managed with a chest-tube and the temporary removal of one or more valves, while another (b)(4) of the events were managed with a chest-tube and removal of all the implanted valves.Upon successful resolution of the pneumothorax, removed valves can be replaced.Patients that experienced a pneumothorax experienced clinical benefits of the zephyr valve treatment that were similar to the benefits experienced by patients who did not have a pneumothorax.The zephyr ebv system ifu and pulmonx training program both specifically reference pneumothorax as a known side effect of this procedure and the published guidelines (valipour, arschang, et al."expert statement: pneumothorax associated with endoscopic valve therapy for emphysema-potential mechanisms, treatment algorithm, and case examples." respiration 87.6 (2014): 513-521).The reported event aligns with the experience observed in the liberate clinical study and is an expected side effect to the zephyr valve treatment.
Event or Problem Description
The patient had a bronchoscopic lung volume reduction procedure with four zephyr valves (three 4.0 ebvs, one 5.5 ebv) placed in the left upper lobe (lul) on (b)(6) 2023.The physician did a bronchoscopy on (b)(6) 2023 (standard practice per the physician), and the valves looked good.The patient was discharged on (b)(6) 2023 and returned within 24 hours with a tension pneumothorax.A chest tube was inserted and the patient was intubated on (b)(6) 2023.Two valves were removed on (b)(6) 2023; (5.5 ebv from the lingula and 4.0 ebv from anterior).On (b)(6) 2023, the remaining two 4.0 ebv valves in the apical and posterior were removed.On (b)(6) 2023, after resolution the chest tube was removed.The patient was discharged from the hospital on (b)(6) 2023.

• Brand Name: ZEPHYR ENDOBRONCHIAL VALVE
• Common Device Name: ENDOBRONCHIAL VALVE
• Manufacturer (Section D): PULMONX CORPORATION; 700 chesapeake drive; redwood city CA 94063
• Manufacturer Contact: mahtab fatemi ; 700 chesapeake drive; redwood city, CA 94063 ; 6504072823
• MDR Report Key: 18087267
• Report Number: 3007797756-2023-00199
• Device Sequence Number: 20490204
• Product Code: NJK
• UDI-Device Identifier: 00811907030324
• UDI-Public: (01)00811907030324(10)506215V71(17)240629
• Combination Product (Y/N): N
• Initial Reporter State: CA
• Initial Reporter Country: US
• PMA/510(K) Number: P180002
• Number of Events Summarized: 1
• Summary Report (Y/N): N
• Device Implanted Year: 2023
• Device Explanted Year: 2023
• Serviced by Third Party (Y/N): Unknown
• Reporter Type: Manufacturer
• Report Source: Health Professional,User Facility,Company Representative
• Initial Reporter Occupation: Other
• Remedial Action: Patient Monitoring
• Type of Report: Initial,Followup
• Report Date (Section B): 11/20/2023

1 Device was Involved in the Event

1 Patient was Involved in the Event

• Is this an Adverse Event Report?: Yes
• Is this a Product Problem Report?: No
• Operator of Device: Health Professional
• Device Expiration Date: 06/29/2024
• Device Model Number: ZEPHYR 5.5 EBV
• Device Catalogue Number: EBV-TS-5.5
• Device Lot Number: 506215-V7.1
• Was Device Available for Evaluation?: No
• Is the Reporter a Health Professional?: No
• Type of Report(Section G): Thirty-Day
• Initial Date Received by Manufacturer: 10/16/2023
• Supplement Date Received by Manufacturer: 10/16/2023
• Initial Report FDA Received Date: 11/07/2023
• Supplement Report FDA Received Date: 11/20/2023
• Was Device Evaluated by Manufacturer? (Y/N): No
• Date Device Manufactured: 06/29/2022
• Is the Device Labeled for Single Use? (Y/N): Yes
• Is This a Single-Use Device that was Reprocessed and Reused on a Patient? (Y/N): No
• Usage of Device: Initial
• Patient Sequence Number: 1
• Outcome Attributed to Adverse Event: Required Intervention; Hospitalization
• Patient Age: 60 YR
• Patient Sex: Male
• Patient Weight: 97 KG
• Patient Ethnicity: Non Hispanic
• Patient Race: Black Or African American